Annexon Shares Soar Following Positive Results from Guillain-Barré Study

Annexon Inc's shares rose by 12% following the announcement of positive top-line results from a study evaluating its immunotherapy, ANX005. The drug developer reported that the study's findings support the potential use of ANX005 as a treatment option for Guillain-Barré Syndrome. Guillain-Barré Syndrome is a rare and acute neuromuscular disease. The study in question was a real-world evidence-based study comparing the effects of ANX005 to those of intravenous immunoglobulin in a matched patient cohort. The objective was to assess the efficacy of ANX005 in the treatment of Guillain-Barré Syndrome, for which there are currently no FDA-approved therapies. The company’s stock reacted positively to this news, reflecting investor optimism regarding ANX005's potential market opportunities.